|
1
|
Wang EY, Dixson J, Schiller NB and Whooley
MA: Causes and predictors of death in patients with coronary heart
disease (from the heart and soul study). Am J Cardiol. 119:27–34.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Woods SE: Primary prevention of coronary
heart disease in women. Should asymptomatic women 50 years of age
take aspirin regularly? Arch Fam Med. 3:361–364. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Menotti A, Puddu PE, Adachi H, Kafatos A,
Tolonen H and Kromhout D: The strength of the multivariable
associations of major risk factors predicting coronary heart
disease mortality is homogeneous across different areas of the
Seven Countries Study during 50-year follow-up. Acta Cardiol.
8:1–7. 2017.
|
|
4
|
Brown JP, Clark AM, Dalal H, Welch K and
Taylor RS: Patient education in the contemporary management of
coronary heart disease. Cochrane Database Syst Rev.
2010:CD0088952010.PubMed/NCBI
|
|
5
|
Lebwohl B, Cao Y, Zong G, Hu FB, Green
PHR, Neugut AI, Rimm EB, Sampson L, Dougherty LW, Giovannucci E, et
al: Long term gluten consumption in adults without celiac disease
and risk of coronary heart disease: Prospective cohort study. BMJ.
357:j18922017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee JS, Chang PY, Zhang Y, Kizer JR, Best
LG and Howard BV: Triglyceride and HDL-C dyslipidemia and risks of
coronary heart disease and ischemic stroke by glycemic
dysregulation status: The strong heart study. Diabetes Care.
40:529–537. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lu W, Zhu Y, Han Z, Wang X, Wang X and Qiu
C: Drug-coated balloon in combination with bare metal stent
strategy for de novo coronary artery disease: A PRISMA-compliant
meta-analysis of randomized clinical trials. Medicine (Baltimore).
96:e63972017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Serban MC, Muntner P and Rosenson RS:
Reply: Statin intolerance and risk for recurrent myocardial
infarction, Coronary heart disease events, and all-cause mortality.
J Am Coll Cardiol. 70:685–686. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wiklund O, Mattsson-Hultén L, Hurt-Camejo
E and Oscarsson J: Effects of simvastatin and atorvastatin on
inflammation markers in plasma. J Intern Med. 251:338–347. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhao Y, Peng R, Zhao W, Liu Q, Guo Y, Zhao
S and Xu D: Zhibitai and low-dose atorvastatin reduce blood lipids
and inflammation in patients with coronary artery disease. Medicine
(Baltimore). 96:e61042017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ricci F, De Caterina R and Fedorowski A:
Orthostatic hypotension: Epidemiology, prognosis, and treatment. J
Am Coll Cardiol. 66:848–860. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu PY, Li YH, Tsai WC, Chao TH, Tsai LM,
Wu HL and Chen JH: Prognostic value and the changes of plasma
levels of secretory type II phospholipase A2 in patients with
coronary artery disease undergoing percutaneous coronary
intervention. Eur Heart J. 24:1824–1832. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Holmes MV, Exeter HJ, Folkersen L, Nelson
CP, Guardiola M, Cooper JA, Sofat R, Boekholdt SM, Khaw KT, Li KW,
et al: CARDIoGRAM Consortium: Novel genetic approach to investigate
the role of plasma secretory phospholipase A2 (sPLA2)-V isoenzyme
in coronary heart disease: Modified Mendelian randomization
analysis using PLA2G5 expression levels. Circ Cardiovasc Genet.
7:144–150. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dickson Vaughan V, Lee CS, Yehle KS, Mola
A, Faulkner KM and Riegel B: Psychometric testing of the Self-Care
of coronary heart disease inventory (SC-CHDI). Res Nurs Health.
40:15–22. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Huang L, Zheng Y, Yuan X, Ma Y, Xie G,
Wang W, Chen H and Shen L: Decreased frequencies and impaired
functions of the CD31+ subpopulation in Treg
cells associated with decreased FoxP3 expression and enhanced Treg
cell defects in patients with coronary heart disease. Clin Exp
Immunol. 187:441–454. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tang SS, Xu S, Cheng J, Cai MY, Chen L,
Liang LL, Yang XL, Chen C, Liu XG and Xiong XD: Two tagSNPs
rs352493 and rs3760908 within SIRT6 gene are associated with the
severity of coronary artery disease in a chinese han population.
Dis Markers. 2016:16280412016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
McLaren JE, Michael DR, Ashlin TG and
Ramji DP: Cytokines, macrophage lipid metabolism and foam cells:
Implications for cardiovascular disease therapy. Prog Lipid Res.
50:331–347. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wu G, Li GB and Dai B: Association of KIF6
variant with lipid level and angiographic coronary artery disease
events risk in the Han Chinese population. Molecules.
17:11269–11280. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ntekim OE, Allard JS, Ngwa JS, Johnson AA,
Castor C, Iyalomhe O, Fungwe TV, Ntekim CC and Obisesan T: Additive
effects of capsaicin oleoresin, irbesartan and amlodipine besylate
on the blood pressure of spontaneously hypertensive rats. J Med
Plants Res. 10:468–478. 2016. View Article : Google Scholar
|
|
20
|
Strupp M: The results support the use of
atorvastatin in elderly patients with recent stroke or TIA.
Neurology. 73:8172009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xin H, Chen ZY, Lv XB, Liu S, Lian ZX and
Cai SL: Serum secretory phospholipase A2-IIa (sPLA2-IIA) levels in
patients surviving acute myocardial infarction. Eur Rev Med
Pharmacol Sci. 17:999–1004. 2013.PubMed/NCBI
|
|
22
|
Burstein B and Nattel S: Atrial fibrosis:
Mechanisms and clinical relevance in atrial fibrillation. J Am Coll
Cardiol. 51:802–809. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rivard L and Khairy P: Mechanisms,
clinical significance, and prevention of cognitive impairment in
patients with atrial fibrillation. Can J Cardiol. 33:1556–1564.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ikonomidis I and Michalakeas CA:
Phospholipases in cardiovascular diseaseAdvances in Biochemistry in
Health and Disease: Phospholipases in Health and Disease. Tappia PS
and Dhalla NS: 10. Springer; New York: pp. 73–83. 2014
|
|
25
|
Divchev D, Grothusen C, Luchtefeld M,
Thoenes M, Onono F, Koch R, Drexler H and Schieffer B: Impact of a
combined treatment of angiotensin II type 1 receptor blockade and
3-hydroxy-3-methyl-glutaryl-CoA-reductase inhibition on secretory
phospholipase A2-type IIA and low density lipoprotein oxidation in
patients with coronary artery disease. Eur Heart J. 29:1956–1965.
2008. View Article : Google Scholar : PubMed/NCBI
|
